- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04414878
VitaFlow™ II Transcatheter Aortic Valve System Pre-market Trial
May 31, 2020 updated by: Shanghai MicroPort CardioFlow Medtech Co., Ltd.
A Prospective, Multicenter, Single-arm, Objective Performance Clinical Investigation For Evaluation of the Safety and Effectiveness of MicroPort™ CardioFlow VitaFlow ™ II Transcatheter Aortic Valve System in the Treatment of Severe Aortic Valve Stenosis
This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of Microport™ CardioFlow VitaFlow™ II Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This a prospective, multi-center, single-arm, objective performance clinical investigation, aiming to evaluate the safety and effectiveness of Microport™ CardioFlow VitaFlow™ II Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.
A total of 145 subjects will be enrolled in 18 clinical centers within China.
Clinical or telephone follow-up is scheduled at 30 days, 6 months, 12 months, and 2-5 years after valve implantation.
Study Type
Interventional
Enrollment (Anticipated)
145
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bi Jie
- Phone Number: (86)(21)38954600
- Email: jbi@microport.com
Study Contact Backup
- Name: Zhujun Cai, PhD
- Phone Number: (86)(21)38954600
- Email: zjcai@microport.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Fuwai Hospital
-
Contact:
- Yongjian Wu, Prof
- Phone Number: 13701387189
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Zhongshan Hospital
-
Contact:
- Junbo Ge, Prof
- Phone Number: 13901977506
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Mao Chen, Prof
- Phone Number: 18980602046
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- Jian-An Wang, Prof
- Phone Number: 13805786328
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
70 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age≥70 years;
- Symptomatic , severe, aortic valve stenosis : peak velocity ≥4.0m/s, or mean transvalvular gradient ≥40mmHg(1 mmHg=0.133kPa), or effective orifice area<0.8cm² (or EOA index<0.5cm²/m²);
- NYHA≥II class;
- Estimated life-expectancy>12 months after implantation of the prosthetic valve;
- Anatomically suitable for the transcatheter aortic valve implantation procedure;
- The patients considered to high-risk or not suitable for surgical aortic valve replacement (SAVR), as assessed by two or above heart surgeons; The patient has been informed of the nature of the study, is willing to enroll in the study by signing a patient informed consent and agreeing to the scheduled follow up requirement.
Exclusion Criteria:
- Acute myocardial infarction (MI) in last 30 days before the treatment;
- Aortic root anatomy not suitable for the implantation of the transcatheter aortic valve;
- Complicated lesion of the aortic valve (aortic stenosis with severe regurgitation); moderate-severe mitral valve stenosis; severe mitral valve regurgitation; severe tricuspid valve regurgitation;
- Previous implantation of heart valve at any position;
- Hemodynamic instability requiring mechanical hemodynamic support devices;
- Need for emergency surgery for any reason;
- Hypertrophic cardiomyopathy with obstruction;
- Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20%;Severe right ventricular dysfunction;
- Active peptic ulcer or upper gastro-intestinal bleeding within the past 3 months;
- Known hypersensitivity or contraindication to all anticoagulation/antiplatelet regimens, to nitinol, contrast media or other relevant elements.
- Congenital aortic valve stenosis or unicuspid aortic valve;
- Vascular diseases or anatomical condition preventing the device access;
- Active endocarditis or other active infections at the time of treatment;
- Participating in another trial and the primary endpoint is not achieved.
- Inability to comply with the clinical investigation follow-up or other requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm clinical investigation
Subjects in experimental group will be implanted with the VitaFlow™ II Transcatheter Aortic Valve System
|
VitaFlow™ II Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System, loading tools, and a guide-wire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of all-cause mortality at 12 months post implantation
Time Frame: 12 months post implantation
|
Rate of all-cause mortality including cardiovascular and non-cardiovascular death
|
12 months post implantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Valve function-mean prosthetic valve gradient
Time Frame: at 30 days, 6 months, and 1 year post implantation
|
Mean prosthetic valve gradient measured by transthoracic echocardiography (TTE)(in mmHg)
|
at 30 days, 6 months, and 1 year post implantation
|
Valve function- effective orifice area
Time Frame: at 30 days, 6 months, and 1 year post implantation
|
Effective orifice area measured by transthoracic echocardiography (TTE)(in cm^2)
|
at 30 days, 6 months, and 1 year post implantation
|
Valve function- degree of prosthetic valve regurgitation
Time Frame: at 30 days, 6 months, and 1 year post implantation
|
Degree of prosthetic valve regurgitation including paravalvular leak and intravalvular regurgitation measured by transthoracic echocardiography (TTE)
|
at 30 days, 6 months, and 1 year post implantation
|
Rate of safety events according to VARC2
Time Frame: at 30 days, 6 months, 1 year and annually up to 5 years post implantation
|
Rate of safety events according to VARC2 including all-cause mortality, myocardial infarction, stroke, bleeding, acute kidney injury, vascular complications, conduction disturbance and arrhythmias, and new permanent pacemaker implantation
|
at 30 days, 6 months, 1 year and annually up to 5 years post implantation
|
Rate of other TAVI-related complications
Time Frame: at 30 days, 6 months, 1 year and annually up to 5 years post implantation
|
Rate of other TAVI-related complications including conversion to open surgery, unplanned use of cardiopulmonary bypass, coronary obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade, endocarditis, valve thrombosis, valve mal-positioning, and TAV-in-TAV
|
at 30 days, 6 months, 1 year and annually up to 5 years post implantation
|
Rate of major adverse cardiac and cerebrovascular events(MACCE)
Time Frame: at 30 days, 6 months, 1 year and annually up to 5 years post implantation
|
Rate of MACCE including all-cause mortality, stroke, myocardial infarction, re-intervention, arrhythmias, and conduction disturbances
|
at 30 days, 6 months, 1 year and annually up to 5 years post implantation
|
Rate of device success
Time Frame: at immediate post implantation
|
Rate of device success, assessed by death, the access, delivery, deployment and implantation of the device, prosthetic valve position and valve function
|
at immediate post implantation
|
Rate of balloon pre-dilation success
Time Frame: at immediate post implantation
|
Rate of balloon pre-dilation success, assessed by the access, delivery, pre-dilation and retrieval of the balloon catheter
|
at immediate post implantation
|
Rate of balloon post-dilation success
Time Frame: at immediate post implantation
|
Rate of balloon post-dilation success, assessed by the access, delivery, post-dilation and retrieval of the balloon catheter
|
at immediate post implantation
|
Rate of procedure success
Time Frame: at immediate post implantation
|
Rate of procedure success, assessed by the device success and the peri-procedural complications
|
at immediate post implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2018
Primary Completion (Anticipated)
January 31, 2022
Study Completion (Anticipated)
January 31, 2027
Study Registration Dates
First Submitted
May 27, 2020
First Submitted That Met QC Criteria
May 31, 2020
First Posted (Actual)
June 4, 2020
Study Record Updates
Last Update Posted (Actual)
June 4, 2020
Last Update Submitted That Met QC Criteria
May 31, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SUPERIOR-2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Hospices Civils de LyonRecruiting
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting
Clinical Trials on VitaFlow™ II Transcatheter Aortic Valve System
-
Shanghai MicroPort CardioFlow Medtech Co., Ltd.Unknown
-
Shanghai MicroPort CardioFlow Medtech Co., Ltd.RecruitingAortic Valve StenosisChina
-
Shanghai MicroPort CardioFlow Medtech Co., Ltd.Not yet recruitingAortic Valve Stenosis
-
Shanghai MicroPort CardioFlow Medtech Co., Ltd.Not yet recruitingAortic Valve Stenosis | Aortic Valve DiseaseChina
-
Shanghai NewMed Medical Co., Ltd.West China Hospital; The General Hospital of Northern Theater CommandRecruiting
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
Nanjing First Hospital, Nanjing Medical UniversityRecruiting
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Xijing HospitalRecruiting
-
Xijing HospitalRecruitingAortic Valve Disease MixedChina